Artivion, Inc. (NYSE:AORT) Insider John E. Davis Sells 10,802 Shares

Key Points

• Insider John E. Davis sold 10,802 shares of Artivion, Inc. for approximately $471,723.34, reducing their ownership by 4.92%.
• Artivion reported $0.24 earnings per share for the last quarter, surpassing analyst estimates and showing a 15.3% increase in revenue year-over-year.
• Brokerages have issued a consensus rating of "Buy" for Artivion, with a price target averaging $39.80, as several firms raised their price objectives following positive earnings.

Artivion, Inc. (NYSE:AORT - Get Free Report) insider John E. Davis sold 10,802 shares of Artivion stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total transaction of $471,723.34. Following the completion of the sale, the insider owned 208,778 shares in the company, valued at approximately $9,117,335.26. This trade represents a 4.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Artivion Trading Down 0.4%

Shares of AORT stock traded down $0.17 during trading hours on Friday, hitting $42.78. 502,276 shares of the company were exchanged, compared to its average volume of 535,231. The firm has a market cap of $2.02 billion, a PE ratio of -101.86 and a beta of 1.64. Artivion, Inc. has a 1 year low of $21.97 and a 1 year high of $43.97. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52. The firm has a fifty day moving average of $32.22 and a 200 day moving average of $28.43.

Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.11 by $0.13. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The firm had revenue of $112.97 million for the quarter, compared to analyst estimates of $107.96 million. The company's revenue was up 15.3% compared to the same quarter last year. Analysts expect that Artivion, Inc. will post 0.37 earnings per share for the current year.

Institutional Trading of Artivion

Several large investors have recently bought and sold shares of the company. Franklin Resources Inc. raised its stake in shares of Artivion by 1.9% during the second quarter. Franklin Resources Inc. now owns 29,263 shares of the company's stock valued at $910,000 after purchasing an additional 533 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock valued at $52,000 after purchasing an additional 538 shares in the last quarter. Illinois Municipal Retirement Fund raised its stake in shares of Artivion by 3.1% during the first quarter. Illinois Municipal Retirement Fund now owns 20,519 shares of the company's stock valued at $504,000 after purchasing an additional 611 shares in the last quarter. MCF Advisors LLC raised its stake in shares of Artivion by 109.3% during the first quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock valued at $29,000 after purchasing an additional 614 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Artivion by 3.3% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,559 shares of the company's stock valued at $645,000 after purchasing an additional 727 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on AORT shares. Canaccord Genuity Group lifted their price target on shares of Artivion from $35.00 to $41.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Stifel Nicolaus boosted their price target on shares of Artivion from $36.00 to $40.00 and gave the stock a "buy" rating in a report on Friday, August 8th. Citizens Jmp upgraded shares of Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. LADENBURG THALM/SH SH cut shares of Artivion from a "buy" rating to a "neutral" rating and boosted their price target for the stock from $32.00 to $38.80 in a report on Wednesday. Finally, Oppenheimer restated an "outperform" rating on shares of Artivion in a research report on Friday, August 8th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $39.80.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.